Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant MAGNETISMM-7
Verified

What's the purpose of this trial?

The goal of this clinical trial is to compare the safety and effectiveness of Elranatamab versus Lenalidomide in participants with newly diagnosed multiple myeloma who have recently undergone autologous stem cell transplant. 

This trial is currently open and accepting patients.


What will happen during the trial?

This study is being conducted in three different parts (or arms). The two arms in this study that are open for enrollment are Arms B and C. Arm A is no longer open for patient enrollment. In Arm B, participants will receive Lenalidomide as maintenance therapy, and in Arm C participants will receive Elranatamab as maintenance therapy.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • Have measurable disease as defined by the trial criteria.
  • Have had 3-8 cycles of induction therapy followed by high dose chemotherapy and autologous stem cell transplant for newly diagnosed multiple myeloma. Your stem cell transplant must have been in the last 120 days before joining this trial. For patients who are receiving consolidation (or maintenance) therapy after their transplant, you must join this trial within 60 days of consolidation therapy, and within 7 months from transplant.
  • Do not have known or active central nervous system involvement of your myeloma.
  • Have not previously had treatment with maintenance therapy for your myeloma.
  • Have not previously had treatment with a BCMA targeted therapy.

Additional Trial Information

Phase 3

Enrollment: 760 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Arizona

Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Gilbert, AZ

Not Yet Accepting

California

UCLA Jonsson Comprehensive Cancer Center University of California Los Angeles

Los Angeles, CA

Open and Accepting

Florida

Miami Cancer Institute Baptist Health South Florida

Miami, FL

Not Yet Accepting

Georgia

Winship Cancer Institute Emory University

Atlanta, GA

Not Yet Accepting

Illinois

Loyola University Medical Center Cardinal Bernardin Cancer Center

Maywood, IL

Not Yet Accepting

Michigan

University of Michigan Comprehensive Cancer Center Rogel Cancer Center

Ann Arbor, MI

Not Yet Accepting

Mississippi

University of Mississippi Medical Center

Jackson, MS

Open and Accepting

New Hampshire

Dartmouth-Hitchcock Medical Center Norris Cotton Cancer Center

Lebanon, NH

Not Yet Accepting

New Jersey

Ohio

Cleveland Clinic - Taussig Cancer Center Taussig Cancer Institute

Cleveland, OH

Not Yet Accepting

OhioHealth Riverside Methodist Hospital

Columbus, OH

Open and Accepting

Texas

Texas Oncology (Dallas)

Dallas, TX

Not Yet Accepting

Baylor Charles A. Sammons Cancer Center Baylor Scott & White Health

Dallas, TX

Not Yet Accepting

Baylor Scott & White Hospital

Temple, TX

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors